title: Therapeutic insulin and hepatic glucose-6-phosphatase activity in preterm infants.
abstract: BACKGROUND
  Hepatic glucose-6-phosphatase activity is low at birth, and in term infants rises rapidly to adult levels. In contrast, in most preterm infants, it remains low postnatally making them vulnerable to repeated hypoglycaemic episodes, resultant cerebral damage, or risk of sudden and unexpected death.
  
  
  OBJECTIVE
  To investigate the clinical features of preterm infants with low glucose-6-phosphatase enzyme activity to determine the influencing factors.
  
  
  METHODS
  Clinical data from 36 preterm infants were correlated by stepwise multiple regression analysis with V(max) of hepatic glucose-6-phosphatase as the dependent variable.
  
  
  RESULTS
  The most significant correlation was with the administration of insulin (units/kg/h postnatal life) with lesser effects of respiratory distress syndrome and dopamine administration. The V(max) changes reflected changes in the level of expression of the glucose-6-phosphatase protein.
  
  
  CONCLUSIONS
  In a variety of animal models, hepatic glucose-6-phosphatase levels have been shown to decrease in response to insulin, which also decreases transcription of the glucose-6-phosphatase gene. The association of insulin administration with high levels of hepatic glucose-6-phosphatase activity and protein expression was therefore most unexpected. Results from model systems, or adults, must be extrapolated to the metabolism of preterm infants with caution.
authors.affiliation: Departments of Obstetrics and Gynaecology and Child Health, Tayside Institute of Child Health, Ninewells Hospital and Medical School, University of Dundee, Dundee DD1 9SY, Scotland, UK. a.burchell@dundee.ac.uk
authors.forename: A
authors.initials: A
authors.lastname: Burchell
authors.forename: A
authors.initials: A
authors.lastname: McGeechan
authors.forename: R
authors.initials: R
authors.lastname: Hume
mesh_terms: D001786:Blood Glucose / Q000032:analysis; D015153:Blotting, Western; D002316:Cardiotonic Agents / Q000008:administration & dosage; D016022:Case-Control Studies; D004298:Dopamine / Q000008:administration & dosage; D004374:Ductus Arteriosus, Patent / Q000150:complications; D005260:Female; D005952:Glucose-6-Phosphatase / Q000378:metabolism*; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature / Q000378:metabolism*; D007328:Insulin / Q000008:administration & dosage / Q000502:physiology*; D008297:Male; D008862:Microsomes, Liver / Q000201:enzymology*; D012044:Regression Analysis; D012127:Respiratory Distress Syndrome, Newborn / Q000150:complications
chemical_list: D001786:Blood Glucose; D002316:Cardiotonic Agents; D007328:Insulin; D005952:Glucose-6-Phosphatase; D004298:Dopamine